Andrea E. Wahner Hendrickson

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial

Kathleen N. Moore, Angeles Alvarez Secord, Melissa A. Geller et al. · The Lancet Oncology · 2019 · 516 citations

Oncology, Metronomic Therapy, Gynecology +6

Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial

Panagiotis A. Konstantinopoulos, Su-Chun Cheng, Andrea E. Wahner Hendrickson et al. · The Lancet Oncology · 2020 · 227 citations · Full text

Medicine, Gemcitabine Versus Gemcitabine, Metronomic Therapy +6

ATR Inhibition Broadly Sensitizes Ovarian Cancer Cells to Chemotherapy Independent of BRCA Status

Catherine J. Huntoon, Karen S. Flatten, Andrea E. Wahner Hendrickson et al. · Cancer Research · 2013 · 207 citations · Full text

Chemotherapy Independent, Oncology, Cell Regulation +15

Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial

Stéphanie Lheureux, Mihaela Cristea, Jeffrey P. Bruce et al. · The Lancet · 2021 · 204 citations · Full text

Medicine, Metronomic Therapy, Clinical Trials +7

Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)

Elizabeth M. Swisher, Tanya T. Kwan, Amit M. Oza et al. · Nature Communications · 2021 · 193 citations · Full text